1. bookVolumen 56 (2022): Heft 4 (October 2022)
Zeitschriftendaten
License
Format
Zeitschrift
eISSN
1336-0329
Erstveröffentlichung
30 Mar 2016
Erscheinungsweise
4 Hefte pro Jahr
Sprachen
Englisch
Uneingeschränkter Zugang

Prolactinoma - which patients react favorably to cabergoline medication?

Online veröffentlicht: 20 Oct 2022
Volumen & Heft: Volumen 56 (2022) - Heft 4 (October 2022)
Seitenbereich: 279 - 283
Zeitschriftendaten
License
Format
Zeitschrift
eISSN
1336-0329
Erstveröffentlichung
30 Mar 2016
Erscheinungsweise
4 Hefte pro Jahr
Sprachen
Englisch

Abbara A, Clarke SA, Nesbitt A, Ali S, Comninos AN, Hatfield E, Martin NM, Sam AH, Meeran K, Dhillo WS. Interpretation of serum gonadotropin levels in hyperprolactinaemia. Neuroendocrinology 107, 2, 105–113, 2018.10.1159/00048926429660734 Search in Google Scholar

Auriemma RS, Pivonello R, Ferreri L, Priscitelli P, Colao A. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am 4, 89–97, 2015.10.1016/j.ecl.2014.10.00725732645 Search in Google Scholar

Ben-Jonathan N, Hugo E. Prolactin (PRL) in adipose tissue: regulation and functions. Adv Exp Med Biol 846, 1–35, 2015.10.1007/978-3-319-12114-7_125472532 Search in Google Scholar

Bernard V, Young J, Binart N. Prolactin – a pleiotropic factor in health and disease. Nat Rev Endocrinol 15, 356–365, 2019.10.1038/s41574-019-0194-630899100 Search in Google Scholar

Bima C, Chiloiro S, Giampietro A, Gessi M, Mattogno PP, Lauretti L, Anile C, Rindi G, Pontecorvi A, De Marinis L, Bianchi A. Galectin-3 and estrogen receptor alpha as prognostic markers in prolactinoma: preliminary results from a pilot study. Front Endocrinol 12, 684055, 2021.10.3389/fendo.2021.684055831224534322092 Search in Google Scholar

Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65, 265–273, 2006.10.1111/j.1365-2265.2006.02562.x16886971 Search in Google Scholar

Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab 33, 101290, 2019.10.1016/j.beem.2019.10129031326373 Search in Google Scholar

Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11, 787–800, 2002.10.1517/13543784.11.6.78712036422 Search in Google Scholar

Colao A, di Sarno A, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148, 325–331, 2003.10.1530/eje.0.148032512611613 Search in Google Scholar

Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82, 2102–2107, 1997.10.1210/jc.82.7.2102 Search in Google Scholar

Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16, 545–553, 2013.10.1007/s11102-012-0454-023239049 Search in Google Scholar

Hu J, Zheng X, Zhang W, Yang H. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary 18, 745–751, 2015.10.1007/s11102-014-0617-225500765 Search in Google Scholar

Kars M, Souverein PC, Herings RM, Romijn JA, Vandenbroucke JP, de Boer A, Dekkers OM. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 94, 2729–2734, 2009.10.1210/jc.2009-017719491225 Search in Google Scholar

Lu C, Liu Y, Lu Z, Huan C. Ki-67 and clinical correlations in patients with resistant prolactinomas. Ann Clin Lab Sci 50, 199–204, 2020. Search in Google Scholar

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96, 273–288, 2011.10.1210/jc.2010-169221296991 Search in Google Scholar

Noronha S, Stokes V, Karavitaki N, Grossman A. Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine 51, 205–210, 2016.10.1007/s12020-015-0727-226336835 Search in Google Scholar

Posawetz AS, Trummer C, Pandis M, Aberer F, Pieber TR, Obermayer-Pietsch B, Pilz S, Theiler-Schwetz V. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study. BMC Endocr Disord 26, 21, 81, 2021. Search in Google Scholar

Sala E, Bellaviti Buttoni P, Malchiodi E, Verrua E, Carosi G, Profka E, Rodari G, Filopanti M, Ferrante E, Spada A, Mantovani G. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. J Endocrinol Invest 39, 1377–1382, 2016.10.1007/s40618-016-0483-z27245604 Search in Google Scholar

Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ, Woodmansee WW, Laws ER Jr. Current indications for the surgical treatment of prolactinomas. J Clin Neurosci 22, 1785–1791, 2015.10.1016/j.jocn.2015.06.00126277642 Search in Google Scholar

Teixeira M, Souteiro P, Carvalho D. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal. Pituitary 20, 464–70, 2017.10.1007/s11102-017-0806-x28523537 Search in Google Scholar

Empfohlene Artikel von Trend MD

Planen Sie Ihre Fernkonferenz mit Scienceendo